MED Medartis AG

Medartis 2023 half-year results presentation

Medartis Holding AG / Key word(s): Half Year Results
Medartis 2023 half-year results presentation

25.07.2023 / 09:00 CET/CEST

INVITATION │ AUDIO WEBCAST

 

We are pleased to invite you to our H1 2023 results presentation on 15 August 2023. The following documents will be published on our and distributed to our newsletter subscribers at approx. 07:00 a.m. CET / Swiss time.

 

(a) Press Release

(b) the Half-year Report

(c) the Conference Presentation

 

If you would like to subscribe to our mailing list, please use the following . The video webcast event will be held in English.

 

Date:

Tuesday, 15 August 2023

Time:

13:00 CEST / Swiss time

Speakers:

Christoph Brönnimann (CEO) and Dirk Kirsten (CFO)


Audio webcast with Q&A:
Webcast participants can submit their questions in writing via the webcast platform or verbally with the telephone line provided below . Please use the latest version of your browser.

 

Participant’s Link (also accessible through our website):

A recording of this online event will be immediately available at the same link for one month, as well as an MP4 file on our website shortly after the conference.

 

You can also connect via the following phone numbers:

 

Zurich:

Geneva :

US:      

UK:          0

Paris:   +33 (0) 1 7037 7166

Berlin :    +49 (0) 30 3001 90612

 

Please dial in 5 minutes before the start of the conference and enter the keyword "Medartis" when prompted by the operator. To place a question verbally please press *1 and to withdraw press *2.

 

 

Kind regards,

 

Medartis Corporate Communications


Phone direct: 4 / 6
Email (investors):
Email (media):

 

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss Exchange: MED / ISIN CH0386200239) is one of the world's leading manufacturers and suppliers of medical devices for the surgical fixation of bone fractures in the upper and lower extremities and the craniomaxillofacial region. Medartis employs more than 860 people in 13 locations and its products are sold in more than 50 countries worldwide. Medartis is committed to providing surgeons and surgical staff with the most innovative titanium implants and instruments, as well as world-class service. For more information, please visit .


Contact:
Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Switzerland
Phone: 4


Medartis US
1195 Polk Drive
Warsaw, IN 46582, USA
Phone:


End of Media Release
Language: English
Company: Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Switzerland
Phone: 4
Fax: 0
E-mail:
Internet:
ISIN: CH0386200239
Valor: 38620023
Listed: SIX Swiss Exchange
EQS News ID: 1687141

 
End of News EQS News Service

1687141  25.07.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1687141&application_name=news&site_id=research_pool
EN
25/07/2023

Underlying

MEDMedartis AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medartis AG

Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: Solid finish to 2024 with numerous strategic plans for 2025

Medartis reported FY2024 core sales growth of 11.7% (CER), placing it at the lower end of its updated guidance range of 12–15% post-H1, with total sales reaching CHF224.8mm (CHF219.6m core). Profitability outperformed expectations, delivering a 19.0% core EBITDA margin—up 1.9PP YoY versus guidance

03/18/25 March 18, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: revising expectations ahead of FY'24 earnings, PT adjusted t...

Medartis faced a volatile market in 2024, marked by a CEO transition and weaker-than-expected H1 performance in key geographies, prompting a downward revision of FY sales guidance to 12–15% CER (from 15–17%). Nonetheless, Medartis maintained its EBITDA margin guidance at ~15% CER, supported by cost

02/10/25 February 10, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: US and EMEA sales ramp up but FY guidance downgraded

In H1 2024, the company reported underlying sales growth of 13.1% (CER), with total growth including third-party manufacturing at 10.8% CER, resulting in net sales of CHF 111.5m (CHF 103.3m). The US market led with a YoY growth of 20.6%, followed by EMEA at 17.8%, while growth in APAC and LATAM was

08/20/24 August 20, 2024 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis appoints Matthias Schupp as new CEO

Only a few weeks after CEO Christoph Brönnimann's step-down announcement, we are pleased to see that Medartis has appointed a well-seasoned medical tech professional with a strong track record in leadership. Matthias has more than 30 years of experience in the industry, having held various senior l

07/09/24 July 9, 2024 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: successfully placed CHF 115.8m convertible bonds due 2031

Medartis announced the successful placement of senior unsecured guaranteed convertible bonds due in 2031, totalling CHF 115.8 million through Accelerated Bookbuilding initiated yesterday post-market. Settlement of the bonds is anticipated on 11th April 2024, with an application for trading admissio

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch